The authors categorize resistance into EGFR-dependent mechanisms (e.g., secondary mutations like T790M and C797S), bypass pathway activation (e.g., MET or HER2 amplification, KRAS mutations, and BRAF mutations), and histologic transformation (e.g., small-cell lung cancer). Here, ERBB2 is linked to small cell lung carcinoma.